Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=54870PROSPECTUS SUMMARY Corgentech is a biopharmaceutical company focused on the discovery, development and commercialization of a new class of therapeutics called transcription factor decoys, or TF decoys. Our TF decoys are short strands of DNA that specifically bind to and block the activity of their target transcription factors. Transcription factors are specialized DNA-binding proteins that specifically bind to the regulatory regions of a target gene or, more often, a set of functionally related target genes and regulate the expression of those genes and their biological processes. Because abnormal gene expression is a fundamental cause of many diseases, blockade of the transcription factors that regulate gene expression offers an attractive therapeutic approach to treat many unmet medical needs. We are focused on TF decoys initially for the treatment of cardiovascular disease, inflammatory disease, such as arthritis, and cancer. We are creating a pipeline of novel therapeutics based on our proprietary TF decoy technology. Our lead product candidate, E2F Decoy, a combination drug and delivery device, is currently in two Phase 3 clinical trials for the prevention of vein graft failure. In September 2003, we completed patient enrollment for both of our Phase 3 clinical trials. We are also developing E2F Decoy for the prevention of arterio-venous, or AV, graft failure and intend to begin Phase 1/2 clinical trials for this indication in the first half of 2004. E2F Decoy has received Fast Track designation from the FDA for both the prevention of vein graft failure and AV graft failure. We have entered into a world-wide collaborative agreement with Bristol-Myers Squibb Company, or BMS, for the development and commercialization of E2F Decoy for all indications. We also have additional TF decoys in preclinical development for the treatment of inflammatory diseases and cancer. The Market Opportunity for Our Lead Product Candidate. Bypass graft surgery is one of the most common surgical procedures in the United States. This procedure involves using sections of a patient's vein to bypass clogged arteries that transport blood to the heart or leg by rerouting blood around the clogged artery. There are two types of bypass graft procedures, both of which are performed to improve the flow of blood and oxygen to the affected organ or limb. Coronary Artery Bypass Graft, or CABG, surgery involves rerouting the flow of blood to the heart, while Peripheral Artery Bypass Graft, or PBG, surgery involves rerouting the flow of blood to the legs. In 2000, approximately 375,000 and 120,000 patients underwent CABG and PBG surgery, respectively, in the United States. While CABG and PBG surgeries are very effective procedures, these grafts often fail due to abnormal cell growth that results in a narrowing of the vein. In the case of CABG surgery, approximately 19% of these grafts fail within the first year with the failure rate increasing...https://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=5487038013210